T1	p 114 205	patients with acute myeloid leukemia and myelodysplastic syndromes : a Japanese multicenter
T2	p 394 507	patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .
T3	p 541 566	systemic fungal infection
T4	p 1337 1361	patients with AML or MDS
T5	i 33 79	itraconazole capsules and fluconazole capsules
T6	i 338 351	fluconazole (
T7	i 362 378	and itraconazole
T8	i 574 586	itraconazole
T9	i 649 660	fluconazole
T10	i 882 894	itraconazole
T11	i 913 924	fluconazole
T12	i 1152 1163	fluconazole
T13	i 1227 1239	itraconazole
T14	i 1413 1425	itraconazole
T15	i 1501 1514	fluconazole .
T16	o 669 683	Adverse events
T17	o 853 863	infections
T18	o 1122 1144	frequency of infection
T19	o 1324 1333	tolerated